We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-1.84%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.85B
AUM Growth
+$135M
Cap. Flow
-$194M
Cap. Flow %
-10.46%
Top 10 Hldgs %
58.55%
Holding
374
New
79
Increased
68
Reduced
92
Closed
116

Top Buys

Rank Stock Value
1
BIOA
BioAmber Inc.
BIOA
+$5.55M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.2M
3
OTIC
Otonomy, Inc.
OTIC
+$3.92M
4
BLRX
BioLineRX
BLRX
+$3.37M
5
SLS icon
SELLAS Life Sciences
SLS
+$2.7M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$62.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$59.7M
3
AMGN icon
Amgen
AMGN
+$35.8M
4
LLY icon
Eli Lilly
LLY
+$15.7M
5
BIIB icon
Biogen
BIIB
+$5.67M

Sector Composition

Rank Sector Weight
1 Miscellaneous 92.69%
2 Healthcare 6.69%
3 Materials 0.25%
4 Financials 0.16%
5 Technology 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MBAI
176
MBody AI Ltd. Ordinary Share
MBAI
$8.76M
$527K 0.03%
149
-193
-56% -$733K
AVEO
177
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$513K 0.03%
+86,890
New +$628K
ARMP icon
178
Armata Pharmaceuticals
ARMP
$170M
$507K 0.03%
2,178
-8,671
-80% -$589K
ARAV
179
CALL
DELISTED
Aravive, Inc. Common Stock
ARAV
$506K 0.03%
+40
New +$4.22K
RXIIW
180
DELISTED
RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021
RXIIW
$492K 0.03%
2,238,487
-31,796
-1% -$5.62K
KA
181
DELISTED
Kineta, Inc. Common Stock
KA
$467K 0.03%
+426
New +$787K
GRDX
182
GridAI Technologies Corp
GRDX
$20.5M
$462K 0.02%
1
– –
ONSIZ
183
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$456K 0.02%
930,272
– –
IOVA icon
184
Iovance Biotherapeutics
IOVA
$4.18B
$448K 0.02%
60,156
-165,925
-73% -$1.22M
IMUC
185
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
$445K 0.02%
139,912
-20,217
-13% -$52.8K
CYTR
186
DELISTED
CytRx Corp
CYTR
$440K 0.02%
164,933
-618,034
-79% -$1.56M
ADMS
187
PUT
DELISTED
Adamas Pharmaceuticals
ADMS
$439K 0.02%
+931
New +$15.9K
SSKN
188
DELISTED
Strata Skin Sciences
SSKN
$428K 0.02%
14,160
-6,536
-32% -$186K
PTLA
189
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$419K 0.02%
107
– –
ALKS icon
190
CALL
Alkermes
ALKS
$7.59B
$418K 0.02%
708
-931
-57% -$52.8K
LXRX icon
191
Lexicon Pharmaceuticals
LXRX
$859M
$410K 0.02%
28,626
-41,414
-59% -$614K
PBYI icon
192
Puma Biotechnology
PBYI
$484M
$394K 0.02%
10,600
-92,643
-90% -$3.38M
SLS icon
193
CALL
SELLAS Life Sciences
SLS
$2.28B
$371K 0.02%
+4
New +$6.62K
NTLA icon
194
CALL
Intellia Therapeutics
NTLA
$1.6B
$355K 0.02%
+252
New +$3.38K
EYPT icon
195
EyePoint Inc
EYPT
$323M
$353K 0.02%
20,510
– –
VTGN icon
196
VistaGen Therapeutics
VTGN
$10.7M
$340K 0.02%
5,783
-96
-2% -$7.78K
ADXS
197
PUT
DELISTED
Advaxis Inc
ADXS
$338K 0.02%
28
– –
GPL
198
PUT
DELISTED
Great Panther Mining Limited
GPL
$331K 0.02%
202
+175
+648% +$3.23K
WINT
199
DELISTED
Windtree Therapeutics Inc
WINT
$328K 0.02%
287,522
-46,892
-14% -$60.9K
STML
200
PUT
DELISTED
Stemline Therapeutics, Inc.
STML
$318K 0.02%
+372
New +$3.39K
6 7
8
9 10

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q1 2017 Portfolio in Review

As of Q1 2017, Sabby Management held 374 positions worth $1.85B, up 7.8% from $1.72B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management withdrew a net $194M in Q1 2017, closing 116 positions and reducing 92 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $62.4M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 93% of assets, up from 81% a quarter earlier, followed by Healthcare and Materials.

Against the trend, Sabby Management opened a new position in BioAmber Inc. worth $3.39M.

  • Sabby Management's largest Q1 2017 buy was BioAmber Inc.: 1,460,859 shares worth $3.39M.
  • Sabby Management added most to Otonomy, Inc. in Q1 2017, an estimated $3.92M increase.
  • Sabby Management's biggest Q1 2017 reduction was Amgen, cutting an estimated $35.8M.
  • Sabby Management fully exited Sarepta Therapeutics in Q1 2017, selling an estimated $62.4M.
  • Sabby Management's ten largest holdings make up 59% of its $1.85B portfolio in Q1 2017.
  • Sabby Management opened 79 new positions and closed 116 in Q1 2017.
  • Sabby Management's portfolio value rose 7.8% quarter-over-quarter to $1.85B.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.